Curated News
By: NewsRamp Editorial Staff
October 02, 2026
Nutriband CEO Marks 5 Years on Nasdaq, Updates AVERSA Progress
TLDR
- Nutriband advances AVERSA(TM) Fentanyl toward NDA, gaining a competitive edge in abuse-deterrent transdermal patches.
- Nutriband will manufacture clinical supplies for a Human Abuse Liability study, file an IND, and initiate clinical studies.
- Nutriband's AVERSA(TM) technology aims to prevent fentanyl abuse and accidental exposure, making the world safer.
- Nutriband marks five years on Nasdaq with progress on its abuse-deterrent fentanyl patch from feasibility to commercial scale-up.
Impact - Why it Matters
This news matters because it provides a transparent look at Nutriband's strategic direction and the tangible progress of its lead asset, AVERSA(TM) Fentanyl. For investors, the CEO's letter offers reassurance about the company's commitment to advancing a potentially life-saving abuse-deterrent product through the regulatory pipeline. The outlined milestones, such as the Human Abuse Liability study and IND filing, are critical steps toward commercialization. If successful, AVERSA(TM) could address the ongoing opioid crisis by reducing the abuse potential of fentanyl patches, a significant public health concern. Moreover, the fifth anniversary on Nasdaq underscores the company's longevity and ability to access capital markets, which is essential for funding costly clinical trials. As the opioid epidemic persists, innovative solutions like AVERSA(TM) are increasingly important, and Nutriband's progress could position it as a key player in the pharmaceutical industry.
Summary
Nutriband (NASDAQ: NTRB), a company focused on transdermal pharmaceutical products, announced that CEO Gareth Sheridan has issued a letter to shareholders commemorating the fifth anniversary of its listing on the Nasdaq Capital Market. The letter highlights significant milestones achieved since October 1, 2021, including the progression of its lead product candidate, AVERSA(TM) Fentanyl, from feasibility studies through commercial manufacturing scale-up, expanded patent protection, and ongoing engagement with the U.S. Food and Drug Administration. Sheridan outlined key priorities going forward, such as manufacturing clinical supplies for a Human Abuse Liability study, filing an Investigational New Drug application, initiating clinical studies, and advancing AVERSA(TM) Fentanyl toward a New Drug Application filing.
Nutriband is primarily engaged in developing a portfolio of transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch that incorporates its proprietary AVERSA(TM) abuse-deterrent technology. This technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential and can be integrated into any transdermal patch. The company’s website is www.nutriband.com. Investors can find the latest news and updates in the company’s newsroom at https://ibn.fm/NTRB.
The announcement was distributed through InvestorWire, a specialized communications platform under the IBN umbrella, which is part of a Dynamic Brand Portfolio of over 75 brands. InvestorWire provides wire-grade press release syndication, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions to help companies reach a broad audience of investors, journalists, and consumers. For more information, visit https://www.InvestorWire.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband CEO Marks 5 Years on Nasdaq, Updates AVERSA Progress
